Form 4: United Therapeutics CEO Executes Planned Stock Sales

Martine A. Rothblatt, CEO of United Therapeutics, executed planned stock option exercises and subsequent sales of common stock totaling 8,000 shares.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed transactions involving common stock on December 15 and 16, 2025.
• On December 15, 2025, 4,000 shares of common stock were acquired through the exercise of stock options at an exercise price of $120.26 per share.
• On the same day, 4,000 shares were disposed of through sales: 500 shares at $491.77 and 3,500 shares at a weighted average price of $495.1384 (ranging from $494.94 to $495.42).
• On December 16, 2025, another 4,000 shares of common stock were acquired through the exercise of stock options at an exercise price of $120.26 per share.
• Also on December 16, 2025, 4,000 shares were disposed of through sales: 2,500 shares at a weighted average price of $492.4938 (ranging from $492.245 to $492.67), 1,000 shares at $494, and 500 shares at $497.17.
• All these exercises and sales were conducted pursuant to a pre-arranged 10b5-1 trading plan established on May 2, 2025.
• Following these transactions, direct beneficial ownership of common stock is 130 shares, with indirect ownership totaling 639,193 shares held across various family trusts.
• The 10b5-1 plan is set to continue until December 31, 2025, or until a tranche of 294,000 stock options that expire March 15, 2026, is exhausted.

Sentiment

Score: 5

Explanation: The filing details routine insider transactions (option exercises and sales) executed under a pre-arranged 10b5-1 trading plan, which is generally considered neutral market activity.

Positives

• The CEO is realizing value from previously granted stock options, indicating a personal financial benefit from the company's stock performance.
• Transactions were executed under a pre-arranged 10b5-1 trading plan, which demonstrates transparency and reduces concerns about opportunistic insider selling.

Negatives

• The sale of shares by a key executive, even if planned, can sometimes be interpreted by some investors as a lack of confidence, though this is often a routine part of executive compensation.

Future Outlook

The pre-arranged 10b5-1 trading plan will continue until the earlier of December 31, 2025, or the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026.

Industry Context

This announcement details routine insider transactions by a key executive, which is a common occurrence in publicly traded companies and does not inherently reflect broader industry trends or competitive positioning.

Related Party Transactions

• Indirect beneficial ownership of 639,193 common stock shares is held through various family trusts, including those where the reporting person shares investment power, the spouse is sole trustee/beneficiary, or the reporting person is sole trustee/beneficiary.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, pre-planned transactions, but some may view insider sales with caution.
• Employees: No direct impact mentioned.

Next Steps

• The 10b5-1 trading plan will continue until December 31, 2025, or until a tranche of 294,000 stock options that expire March 15, 2026, is exhausted.

Key Dates

Recommendation

The filing details routine, pre-planned insider transactions by the CEO, involving the exercise of stock options and subsequent sale of shares. These transactions are executed under a 10b5-1 trading plan, which mitigates concerns about opportunistic selling. As such, this filing does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. It is a standard disclosure of executive compensation realization.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Stock Options, 10b5-1 Plan, SEC Form 4, CEO Stock Sale